higher dollar is good to CRXL

[Entendance]

http://investors.crucell.com/C/132631/ir_v2.html

http://www.crucell.com/About%20Us

[Entendance]

Crucell Announces Third Quarter 2008 Results
http://cws.huginonline.com/C/132631/PR/ ... 7_5_5.html
http://www.crucell.com:80/

[Entendance]

Crucell Announces Excellent Results for Influenza Antibody
Leiden, The Netherlands, 11 December 2008 - Dutch biopharmaceutical company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that its monoclonal antibody (mAb) directed against a broad range of influenza virus strains has strongly outperformed the most current anti-influenza drug in preclinical tests.
http://investors.crucell.com/C/132631/ir_v2.html

[Entendance]

Wyeth is in talks to buy Dutch vaccine maker Crucell in a deal that could value Crucell at more than $1.35 billion.
wsjonline

[fpfrazzano]

Dr.E,

Congrats on the Wyeth/Crucell deal. I was aware that Wyeth was looking to broaden their Vaccine base but did not follow this particular relationship. Oh well my loss! Again congrats on this one as I know CRXL was one of the plays we discussed along w/ INFI,EPIX,NABI,SPPI all long plus new positions ASTM,AVII,BPAX,HGSI,HYTM,MMM and STEM.....I can't keep up with you E, you know I am retired now and working harder than before I retired!

LOL!

I have my first copy of "Bio-space for beginners Newsletter" completed and that is compounding my frustration. Would you like to see a copy? I will email to you if you want to take a look?

Best Regards,

Frank

[Entendance]

LOL!

I have my first copy of "Bio-space for beginners Newsletter" completed and that is compounding my frustration. Would you like to see a copy? I will email to you if you want to take a look?

Best Regards,

Frank

Dear Frank, that's the beauty of our beach!
You don't need to mail me, send me instead a private message [check this tool up on your user control panel! ]

[Entendance]

Published: 22:35 07.01.2009 GMT+1 /HUGIN /Source: Crucell N.V. /AEX: CRXL /ISIN: NL0000358562

Crucell and Wyeth in discussion on a combination of the two companies

Leiden, The Netherlands, 7 January 2009 - Dutch biopharmaceutical company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss
Exchange: CRX) today confirms that it is in friendly discussions with Wyeth that may lead to a combination of the two
companies. These discussions are at a preliminary stage and there is no certainty that they will result in a transaction. An
update will be provided in due course.

About Crucell
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a global biopharmaceutical company focused on research,
development, production and marketing of vaccines, proteins and antibodies that prevent and treat infectious diseases. Its
vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a
fully-liquid vaccine against five important childhood diseases and a virosome-adjuvanted vaccine against influenza. Crucell
also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free
hepatitis A vaccine on the market. The Company has a broad development pipeline, with several product candidates based on
its unique PER.C6® production technology. The Company licenses its PER.C6® technology and other technologies to the
biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi-aventis, Novartis, Wyeth and
Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with subsidiaries in Switzerland, Spain, Portugal, Italy,
Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit http://www.crucell.com.

[Entendance]

We think this is JUST the start of a bidding fight; we follow CRXL since 2005 and we know why WYE craves for it.
http://investors.crucell.com/C/132631/ir_v2.html

[Entendance]

In order to make correct comparisons! members and guests investing in CRXL: remember to check also
http://www.dailyfx.com/
http://investors.crucell.com/C/132631/ir_v2.html
and...be careful with your stop orders! Someone could regret bad moves!
http://www.theessentialsoftrading.com/B ... op-orders/

[Entendance]

JANUARY 23, 2009 - wsjonline
Pfizer Inc. is in talks to acquire rival drug maker Wyeth in a deal that could be valued at more than $60 billion, said people familiar with the matter. A combination of these two U.S. pharmaceutical giants would redraw the boundaries of the global drug industry, which has suffered from flagging product development and high fixed costs. It would also represent a high-stakes gambit for Pfizer, which has been stung in the past by expensive acquisitions. The two sides have been in discussions for months and a deal isn't imminent, the people said. Given recent market volatility and overall economic uncertainty, the talks are especially fragile and could collapse, the people warned. Pfizer spokesman Raymond F. Kerins Jr. said the company doesn't comment on "market rumors and speculation." A Wyeth spokesman said, "We don't comment on marketplace rumor."